Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial.
Martínez-García M, Velasco G, Pineda E, Gil-Gil M, Alameda F, Capellades J, Martín-Soberón MC, López-Valero I, Tovar Ambel E, Foro P, Taus Á, Arumi M, Hernández-Laín A, Sepúlveda-Sánchez JM. Martínez-García M, et al. Among authors: capellades j. Cancers (Basel). 2022 May 12;14(10):2393. doi: 10.3390/cancers14102393. Cancers (Basel). 2022. PMID: 35625997 Free PMC article.
Pseudoprogression as an adverse event of glioblastoma therapy.
Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F; GLIOCAT Group. Balaña C, et al. Among authors: capellades j. Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3. Cancer Med. 2017. PMID: 29105360 Free PMC article.
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Balana C, et al. Among authors: capellades j. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. J Neurooncol. 2016. PMID: 26847813 Clinical Trial.
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Sepúlveda JM, Belda-Iniesta C, Gil-Gil M, Pérez-Segura P, Berrocal A, Reynés G, Gallego O, Capellades J, Ordoñez JM, La Orden B, Balañá C. Sepúlveda JM, et al. Among authors: capellades j. Clin Transl Oncol. 2015 Sep;17(9):743-50. doi: 10.1007/s12094-015-1304-0. Epub 2015 Jun 2. Clin Transl Oncol. 2015. PMID: 26033428 Clinical Trial.
Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
Carrato C, Alameda F, Esteve-Codina A, Pineda E, Arpí O, Martinez-García M, Mallo M, Gut M, Lopez-Martos R, Barco SD, Ribalta T, Capellades J, Puig J, Gallego O, Mesia C, Muñoz-Marmol AM, Archilla I, Arumí M, Blanc JM, Bellosillo B, Menendez S, Esteve A, Bagué S, Hernandez A, Craven-Bartle J, Fuentes R, Vidal N, Aldecoa I, Iglesia N, Balana C. Carrato C, et al. Among authors: capellades j. Clin Cancer Res. 2020 Dec 15;26(24):6600-6609. doi: 10.1158/1078-0432.CCR-20-2171. Epub 2020 Sep 30. Clin Cancer Res. 2020. PMID: 32998960
RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma.
Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí O, Martinez-García M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil-Gil M, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardús A, Bellosillo B, Muñoz-Marmol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J, Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C. Esteve-Codina A, et al. Among authors: capellades j. Clin Cancer Res. 2021 Jan 15;27(2):645-655. doi: 10.1158/1078-0432.CCR-20-2141. Epub 2020 Oct 26. Clin Cancer Res. 2021. PMID: 33106291
Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
Molina D, Pérez-Beteta J, Martínez-González A, Sepúlveda JM, Peralta S, Gil-Gil MJ, Reynes G, Herrero A, De Las Peñas R, Luque R, Capellades J, Balaña C, Pérez-García VM. Molina D, et al. Among authors: capellades j. PLoS One. 2016 Aug 24;11(8):e0161484. doi: 10.1371/journal.pone.0161484. eCollection 2016. PLoS One. 2016. PMID: 27557121 Free PMC article.
Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma.
Puig J, Biarnés C, Daunis-I-Estadella P, Blasco G, Gimeno A, Essig M, Balaña C, Alberich-Bayarri A, Jimenez-Pastor A, Camacho E, Thio-Henestrosa S, Capellades J, Sanchez-Gonzalez J, Navas-Martí M, Domenech-Ximenos B, Del Barco S, Puigdemont M, Leiva-Salinas C, Wintermark M, Nael K, Jain R, Pedraza S. Puig J, et al. Among authors: capellades j. Cancers (Basel). 2019 Jan 14;11(1):84. doi: 10.3390/cancers11010084. Cancers (Basel). 2019. PMID: 30646519 Free PMC article.
85 results